Oral Idasanutlin in Patients with Polycythemia Vera.
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood.2018893545
Abstract: A limited number of drugs are available to treat patients with polycythemia vera (PV) and essential thrombocythemia (ET). We attempted to identify alternative agents that may target abnormalities within malignant hematopoietic stem and progenitor cells… read more here.
Keywords: oral idasanutlin; polycythemia vera; idasanutlin patients; patients polycythemia ... See more keywords
The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia
Sign Up to like & getrecommendations! Published in 2018 at "Cancers"
DOI: 10.3390/cancers10060170
Abstract: The tumor suppressor protein p53 is inactivated in a large variety of cancer cells. Cellular p53 inhibitors like the mouse double minute 2 homolog (MDM2) commonly suppress the p53 function in acute myeloid leukemia (AML).… read more here.
Keywords: inhibitor; mdm2; treatment; aml ... See more keywords